Rapport Therapeutics, Inc. RAPP Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $78.06M+48.3% | $52.65M-79.1% | $251.36M+356% | $55.07M-4.4% | $57.6M+1.4% | ||
| $398.73M-8.9% | $437.89M+67.3% | $261.67M+27.4% | $205.38M-9.8% | $227.78M— | ||
| —— | —— | —— | —— | —— | ||
| $484.7M-2.8% | $498.56M-4.2% | $520.66M+92.7% | $270.24M-7.1% | $290.97M— | ||
| $2.52M-15.4% | $2.98M-4.5% | $3.12M-1.8% | $3.17M-6.8% | $3.4M— | ||
| $497.6M-2.9% | $512.43M-4.3% | $535.32M+87.5% | $285.5M-5.5% | $302.05M— | ||
| $17.16M+34.7% | $12.74M+21.3% | $10.5M+22.3% | $8.59M+17.8% | $7.29M+81.5% | ||
| $17.9M-6.0% | $19.05M+33.1% | $14.32M+20.5% | $11.88M+26.6% | $9.38M— | ||
| $26.09M-6.1% | $27.78M+17.2% | $23.71M+7.8% | $21.98M+35.6% | $16.22M— | ||
| $48K0.0% | $48K0.0% | $48K+29.7% | $37K0.0% | $37K— | ||
| -$255.09M-8.4% | -$235.23M-16.8% | -$201.47M-15.4% | -$174.54M-18.1% | -$147.81M— | ||
| $471.51M-2.7% | $484.65M-5.3% | $511.62M+94.2% | $263.51M-7.8% | $285.84M-6.4% | ||
| $497.6M-2.9% | $512.43M-4.3% | $535.32M+87.5% | $285.5M-5.5% | $302.05M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Rapport Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 27.08 — current assets exceed current liabilities.
- Where does Rapport Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.